Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc. Common Stock (BCAX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · BCAX · as of Jun 8, 2026
Activity summary
Buy transactions
2
P-Purchase only
Sell transactions
55
12 Months
Buy/Sell ratio
0.04
Buy/Sell (by trades)
Overall sentiment
Bicara Therapeutics Inc. Common Stock insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
BCAX insider buying and selling by quarter
BCAX insider selling · BCAX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · BCAX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
BCAX executive sell shares · BCAX board member insider trading · BCAX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 21, 2026 | Hyep Ivan CFO | Option | 9,200 | $35K | Form 4 |
| May 21, 2026 | Hyep Ivan CFO | Sale | 9,200 | $188K | Form 4 |
| May 18, 2026 | Mazumdar Claire CEO · Director | Option | 15,000 | $57K | Form 4 |
| May 18, 2026 | Mazumdar Claire CEO · Director | Sale | 12,022 | $240K | Form 4 |
| May 18, 2026 | Mazumdar Claire CEO · Director | Sale | 2,978 | $61K | Form 4 |
| May 15, 2026 | Cohlhepp Ryan President and COO · Director | Option | 8,000 | $30K | Form 4 |
| May 15, 2026 | Cohlhepp Ryan President and COO · Director | Sale | 8,000 | $162K | Form 4 |
| May 15, 2026 | Cohlhepp Ryan President and COO · Director | Sale | 4,500 | $91K | Form 4 |
| Apr 27, 2026 | Raben David Chief Medical Officer | Option | 5,500 | $21K | Form 4 |
| Apr 27, 2026 | Raben David Chief Medical Officer | Sale | 5,500 | $126K | Form 4 |
| Apr 21, 2026 | Hyep Ivan CFO | Option | 9,200 | $35K | Form 4 |
| Apr 21, 2026 | Hyep Ivan CFO | Sale | 9,200 | $212K | Form 4 |
| Apr 20, 2026 | Mazumdar Claire CEO · Director | Option | 15,000 | $57K | Form 4 |
| Apr 16, 2026 | Mazumdar Claire CEO · Director | Option | 7,080 | $39K | Form 4 |
| Apr 20, 2026 | Mazumdar Claire CEO · Director | Sale | 15,000 | $354K | Form 4 |
| Apr 16, 2026 | Mazumdar Claire CEO · Director | Option | 7,454 | $28K | Form 4 |
| Apr 16, 2026 | Mazumdar Claire CEO · Director | Option | 8,226 | $36K | Form 4 |
| Apr 15, 2026 | Cohlhepp Ryan President and COO · Director | Option | 8,000 | $30K | Form 4 |
| Apr 15, 2026 | Cohlhepp Ryan President and COO · Director | Sale | 8,000 | $184K | Form 4 |
| Apr 15, 2026 | Cohlhepp Ryan President and COO · Director | Sale | 4,500 | $104K | Form 4 |
| Mar 25, 2026 | Raben David Chief Medical Officer | Option | 5,500 | $21K | Form 4 |
| Mar 25, 2026 | Raben David Chief Medical Officer | Sale | 5,500 | $104K | Form 4 |
| Mar 23, 2026 | Hyep Ivan CFO | Option | 9,200 | $35K | Form 4 |
| Mar 23, 2026 | Hyep Ivan CFO | Sale | 9,200 | $170K | Form 4 |
| Mar 19, 2026 | Mazumdar Claire CEO · Director | Option | 6,905 | $26K | Form 4 |
Cohlhepp Ryan
President and COO · Director
Date
May 15
Shares
8,000
Price
$3.79
Value
$30K
Cohlhepp Ryan
President and COO · Director
Date
May 15
Shares
8,000
Price
$20.29
Value
$162K
Cohlhepp Ryan
President and COO · Director
Date
May 15
Shares
4,500
Price
$20.29
Value
$91K
Raben David
Chief Medical Officer
Date
Apr 27
Shares
5,500
Price
$3.79
Value
$21K
Raben David
Chief Medical Officer
Date
Apr 27
Shares
5,500
Price
$22.88
Value
$126K
Cohlhepp Ryan
President and COO · Director
Date
Apr 15
Shares
8,000
Price
$3.79
Value
$30K
Cohlhepp Ryan
President and COO · Director
Date
Apr 15
Shares
8,000
Price
$23.01
Value
$184K
Cohlhepp Ryan
President and COO · Director
Date
Apr 15
Shares
4,500
Price
$23.01
Value
$104K
Raben David
Chief Medical Officer
Date
Mar 25
Shares
5,500
Price
$3.79
Value
$21K
Raben David
Chief Medical Officer
Date
Mar 25
Shares
5,500
Price
$18.95
Value
$104K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About BCAX insider trading
BCAX insider trades
Bicara Therapeutics Inc. Common Stock (BCAX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Mazumdar Claire (CEO · Director), Cohlhepp Ryan (President and COO · Director), Hyep Ivan (CFO). Over the past 12 months, 5 insiders have filed transactions with the SEC. BCAX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Bicara Therapeutics Inc. Common Stock's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
BCAX insider trading · 5 questionsThe insiders of Bicara Therapeutics Inc. Common Stock (BCAX) include executives and directors such as Mazumdar Claire (CEO · Director), Cohlhepp Ryan (President and COO · Director), Hyep Ivan (CFO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026